S Eswara Reddy rejoins as joint drug controller after Centre revokes suspension

After the Union government revoked his suspension on December 26, former Joint Drug Controller S Eswara Reddy has rejoined the apex drug regulatory body.

The Delhi High Court granted bail to both Reddy and Biocon’s associate vice-president Praveen Kumar.

According to the CBI, three people were arrested in June after they were allegedly bribed to waive off a clinical trial requirement for a diabetes drug developed by Biocon Biologicals. The company, a Biocon subsidiary, has denied the charges.

Reddy was arrested on June 21 for allegedly taking a bribe to waive off the phase-3 clinical trial of the Insulin Aspart injection of Biocon Biologics. On July 19, a CBI court in Delhi rejected his bail application and those of Biocon Biologics’ Associate Vice President L Praveen Kumar and three others.

Reddy alleged that the proceedings were “part of some larger conspiracy not to let him appear for the interview for the above post (DCGI) though despite (CBI) proceedings, no departmental enquiry has been instituted against him”.

He didn’t elaborate on the conspiracy or those who were part of it.

He also told the court that due to his “impeccable career and character”, he was appointed interim Drug Controller of India from February 2018 to August 2019 and was likely to be appointed as such.

Opposing the bail plea, the CBI said they caught Reddy while he was accepting Rs 4 lakh from Dinesh Dua, director at Synergy Network India Private Limited.

Related Posts

  • Pharma
  • June 19, 2024
  • 70 views
Dermatologists Raise Concern Over Rising Skin Conditions In India

Mumbai: Dermatologists have noticed a significant increase in various skin conditions in India in recent years. Issues range from fungal infections, acne and hair loss to pigmentation. Dr. Sonali Kohli, a…

  • Pharma
  • June 19, 2024
  • 115 views
Expert Panel To Soon Weigh Plan To Use Generics For Prescription Drugs

New Delhi: An expert committee is likely to meet soon to deliberate on a contentious proposal to assess the feasibility of allowing generic substitutions for prescription drugs, said people familiar with…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Dermatologists Raise Concern Over Rising Skin Conditions In India

Dermatologists Raise Concern Over Rising Skin Conditions In India

Expert Panel To Soon Weigh Plan To Use Generics For Prescription Drugs

Expert Panel To Soon Weigh Plan To Use Generics For Prescription Drugs

Telangana Anti-Narcotics Bureau Seals Alprazolam Manufacturing Unit

Telangana Anti-Narcotics Bureau Seals Alprazolam Manufacturing Unit

Structurally & Phonetically Similar Trademark Can’t Be Registered: Bombay HC

Structurally & Phonetically Similar Trademark Can’t Be Registered: Bombay HC

FDI Inflow Into Hospitals & Diagnostic Centres Grows 89 Per Cent In 2023-24

FDI Inflow Into Hospitals & Diagnostic Centres Grows 89 Per Cent In 2023-24

Ayush Ministry, Raj Govt Yet To Act Against Firm Selling Homoeopathic ‘Insulin’

Ayush Ministry, Raj Govt Yet To Act Against Firm Selling Homoeopathic ‘Insulin’